Full Press Release Details
LEXINGTON, MA--(Marketwired - Feb 28, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the Cowen and Company 37th Annual Health Care Conference on Monday, March 6, 2017.
Event: Cowen and Company 37th Annual Health Care Conference
Date: Monday, March 6, 2017
Location: Boston Marriott Copley Place, Boston, MA
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. Aldeyra's lead product candidate, ADX-102, is an aldehyde trap in development for ocular inflammation, as well as for Sj gren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism. Aldeyra's product candidates have not been approved for sale in the U.S. or elsewhere.
Contact Information:
Aldeyra Therapeutics, Inc.
Tel: +1 781-761-4904 ext. 205
MacDougall Biomedical Communications